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Sir,
We appreciate the data and comments provided by Abadie et al
(2011) regarding our recent report ‘No association between
germline allele-specific expression of TGFBR1 and colorectal
cancer risk in Caucasian and Ashkenazi populations’ (Segui
et al, 2011). They provide new compelling data corroborating
our latest findings, which indicate that allele-specific expression
(ASE) of TGFBR1 does not confer an increased risk of colorectal
cancer (CRC).
In their letter, Abadie et al criticise the lack of a detailed
description of the subjects studied by Segui et al (2011). In this
study, we show the characteristics of the informative cases and
controls with ASE results that could be evaluated from the
Ashkenazi Jewish and Caucasian cohorts (Table 1).
Abadie et al point out that the significant discrepancies
observed among studies, mostly between the first (Valle et al,
2008) and the following reports (Guda et al, 2009; Carvajal-
Carmona et al, 2010; Tomsic et al, 2010; Segui et al, 2011), may be
partially attributed to the differences in the populations analysed.
The sets of patients and controls analysed by Segui et al (2011)
were obtained from one population-based and one hospital-based
case–control study, with different selection criteria than the cases
and controls selected by Abadie et al. Despite the differences, their
results are in concordance with ours.
Abadie et al carried out the same methodological approach as
Valle et al (2008). Therefore, to approximate the patients’ selection
criteria in both the series in this study, we selected among the
informative CRC cases studied in the original report those with:
(1) CRC diagnosed before 61 years of age with a first-degree
relative affected with CRC and (2) CRC diagnosed before 51 years
of age (Valle et al, 2008). In this subset of cases, the average ASE
value was 1.31 (range 0.79–3.95; n¼63), very different from the
average ASE value 1.07 (range 0.77–1.45; n¼69) obtained by
Abadie et al in CRC cases, also using the SNaPshot technology (PE
Applied Biosystems, Foster City, CA, USA). This observation
suggests that the difference in the study population is not the cause
of discrepancies between the original and subsequent reports.
The results shown by Abadie et al indirectly support that
SNaPshot is especially sensitive to RNA quality. Tomsic et al
(2010) already noticed that high-quality RNA is essential for
reproducibility of ASE. Although poor RNA quality may be the
cause of inconsistent results with SNaPshot or pyrosequencing, the
latter has proved to be a much more robust technique (Tomsic
et al, 2010; Segui et al, 2011). The procedure of blood collection
and processing carried out by Abadie et al ensured very high
RNA quality, probably explaining why SNaPshot provided
consistent values among SNPs and low s.d.’s between independent
replicates, even for rs7871490, a SNP located in a complex
repetitive stretch.
The letter by Abadie et al clarifies the role of ASE of TGFBR1 in
CRC susceptibility. Current evidence suggests that differences
observed among studies are not directly attributable to study
population or technique, provided high-quality RNA is used for
allele expression experiments, and that allele-specific expression of
TGFBR1 is not a strong risk factor for CRC.
Table 1 Characteristics of the informative cases and controls with ASE
results studied by Segui et al (2011)
MECC BCCS
CRC patients n¼96 n¼75
Age at CRC diagnosis (median±s.d.) 56±9.7 66±10.6
Gender M: 46/93 (49%)
F: 47/93 (51%)
M: 41/75 (55%)
F: 34/75 (45%)
CRC family history (X1FDR with CRC) 10/92 (11%) 10/60 (17%)
Ethnicity Ashkenazi Caucasian
Controls n¼90 n¼0
Age at blood collection (median±s.d.) 59±9.8
Gender M: 45/89 (51%)
F: 44/89 (49%)
CRC family history (X1FDR with CRC) 9/89 (10%)
Ethnicity Ashkenazi
Abbreviations: BCCS¼Bellvitge Colorectal Cancer Study; CRC¼colorectal cancer;
F¼female; FDR¼first-degree relative; M¼male; MECC¼Molecular Epidemiology
of Colorectal Cancer; s.d.¼standard deviation. *Correspondence: Dr L Valle; E-mail: lvalle@iconcologia.net
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